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Autophagy, a cellular degradation pathway, can restrict or assist viral replication. In this issue of Cell Host &
Microbe, Beale et al. (2014) report that the influenzavirusmatrixprotein 2binds to theessential autophagypro-
tein LC3 topresumably transport LC3-conjugatedmembranes to the cell surface for buddingof stable viruses.Autophagy describes a group of cellular
pathways that import cytoplasmic con-
stituents into lysosomes for degradation
(Mizushima et al., 2011). Of these,
macroautophagy forms double-mem-
brane-surrounded vesicles, so-called
autophagosomes that engulf parts of the
cytoplasm, even whole organelles, and
transport them to lysosomes. More than
30 essential products of autophagy-
related genes (atgs) are involved in the
formation of these autophagosomes.
One of these, an ubiquitin-like molecule
called Atg8, gets directly coupled to the
forming autophagosome membrane and
is probably involved in its elongation as
well as the recruitment of substrates into
autophagosomes. Light chain 3 (LC3)
proteins are a group of three mammalian
Atg8 orthologs. LC3 mediates substrate
recruitment to autophagosomes via bind-
ing partners that carry LC3-interacting re-
gions (LIR). Among these are proteins
incorporated into organelles that deliver
these for macroautophagy. Others, like
p62/sequestosome 1, carry LIR motifs
and ubiquitin binding domains or bind
to glycosylation-detecting proteins, like
NDP52 (nuclear dot protein 52) to galec-
tin-8, to anchor ubiquitinated substrates
or sugar moieties in the cytosol to forming
autophagosomes (Randow and Mu¨nz,
2012). Thus, LC3 attachment usually
leads to incorporation into autophago-
somes, followed by delivery to and degra-
dation in lysosomes.
These mechanisms are also used
during xenophagy, macroautophagic
degradation of intracellular pathogens,
including viruses. In particular, neuro-
tropic infections with the RNA virus Sen-
dai virus (SeV) have been shown to be
restricted by macroautophagy (Orvedahl
et al., 2010). The SeV capsid gets ubiqui-130 Cell Host & Microbe 15, February 12, 201tinated in this process and binds to p62/
sequestosome 1 for incorporation into
autophagosomes. The ubiquitin-ligase
SMURF1 (SMAD ubiquitination regulatory
factor 1) supports macroautophagy of
SeV and colocalizes with the viral capsid
(Orvedahl et al., 2011). Similarly, another
RNA virus, chikungunya virus (CHIKV),
gets degraded by macroautophagy after
binding to p62/sequestosome 1 (Judith
et al., 2013). This is the predominant inter-
action of CHIKV with the autophagic
machinery in mouse cells. However, in
human cells, CHIKV RNA replication
occurs at a protein complex that is bound
to LC3 at the trans-Golgi network via
NDP52 (Judith et al., 2013). The latter
interaction favors CHIKV replication,
which becomes the dominant function of
the autophagic machinery in human cells.
This example documents that successful
pathogens might not only evade innate
immune restriction by macroautophagy,
but can also use its molecular machinery
for their own benefit.
In this issue of Cell Host & Microbe,
another example for such a pathogen is
investigated. The segmented RNA virus
influenza A virus has been previously
described to block macroautophagy by
inhibiting fusion of LC3-coupled vesicles
with lysosomes (Gannage´ et al., 2009).
This leads to a perinuclear accumulation
of autophagosomes. The viral protein
that achieves this block in autophago-
some maturation is matrix protein 2 (M2),
the proton channel that is essential for
both viral entry and budding from the
cell membrane. Randow and colleagues
now identify a LIR motif in M2 (aa 91–94)
that directs LC3 to the cell membrane,
but does not influence perinuclear LC3
accumulation (Beale et al., 2014) (Fig-
ure 1). This represents the first docu-4 ª2014 Elsevier Inc.mented pathogen-encoded LIR motif. To
prevent the interaction between the M2
LIR and LC3 from promoting M2 or even
virus particle degradation, M2 seems to
have acquired an additional domain that
prevents autophagosome fusion with
lysosomes. The M2-mediated redirection
of LC3 to the plasma membrane might
serve the purpose of delivering LC3-con-
jugated membranes to the cell surface.
Indeed, membrane-consuming filamen-
tous influenza A virus budding is not
observed in the absence of the LIR motif
in M2. Nevertheless, the viral titers that
are produced in the absence or presence
of LC3 redirection to the cell membrane
are similar. However, when the authors
tested the stability of the produced influ-
enza A virus particles after prolonged
time periods (1–2 days) at room tempera-
ture, infectivity of particles that were pro-
duced from influenza A viruses with LIR-
deficient M2 was decreased. Although
LC3 is not incorporated into budding influ-
enza A viruses, the presented evidence
suggests that the viral envelope is
changed by the absence of LC3-coupled
membranes at the cell surface and ren-
ders the resulting viruses less stable.
How LC3 or LC3-coupled membranes
alter influenza A virus envelope composi-
tion requires further investigation.
Several other viruses seem to use the
membrane fusion machinery of macroau-
tophagy for their replication and virus par-
ticle release. Among these are important
human pathogens like poliovirus, hepati-
tis C virus (HCV), and human immunodefi-
ciency virus (HIV) (Dreux et al., 2009;
Jackson et al., 2005; Kyei et al., 2009).
Poliovirus was the first virus for which
perinuclear accumulation of autophagic
membranes was described. The polio-
virus proteins 2BC and 3A are sufficient
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Figure 1. Influenza A Virus Redirects LC3B to the Cell Surface
Influenza A virus arrests autophagosome fusion with lysosomes via its matrix protein 2 (M2). This leads to
perinuclear LC3B-coupled membrane accumulation. Via direct binding to LC3B M2 redirects LC3B and
presumably the associatedmembranes to the cell surface for filamentous influenza A virus budding, which
results in more stable viral particles.
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(Jackson et al., 2005). These membranes
seem to serve as scaffolds for the viral
replication machinery and possibly trans-
port poliovirus particles to the cell surface
for release. HCV and HIV also subvert
macroautophagy for their replication and
release, respectively. At least four essen-
tial autophagy components, including the
LC3 membrane conjugation machinery,
were found to be essential for early trans-
lation of HCV proteins (Dreux et al., 2009).
Once membrane rearrangement has
occurred and HCV infection is estab-
lished, themolecular machinery ofmacro-
autophagy is no longer required for the
replication of this RNA virus. Apart from
using autophagic membranes as replica-
tion scaffolds, some viruses also highjack
them to get out of cells. For example, HIV
blocks autophagosome maturation with
its Nef protein (Kyei et al., 2009). In in-
fected macrophages this assists viralreplication, presumably by supporting
multivesicular body formation, which
could be one of the viral budding sites in
this cell type. Thus, successful pathogens
not only block their degradation by mac-
roautophagy, but also utilize the respec-
tivemolecular machinery to shape cellular
membranes for their replication and
budding needs.
These additional functions of the mac-
roautophagic machinery, in addition to
viral particle degradation, complicate
strategies to therapeutically manipulate
autophagy during viral infections. They
would suggest that each virus’ regulation
of this pathway needs to be analyzed in
order to predict if macroautophagy inhibi-
tion or stimulation should be therapeuti-
cally explored. In addition, the effect of
macroautophagy on extrinsic immune
control of viral infections needs to be
taken into consideration. For example,
macroautophagy inhibition might restrictCell Host & Microbe 15,influenza A virus infection intrinsically in
infected host cells, but both antigen pro-
cessing for MHC presentation by antigen
presenting cells and T cell expansion
might be compromised by this treatment.
Therefore, the type and delivery of auto-
phagy modulators, possibly inhibitors to
lung pneumocytes during influenza infec-
tion via inhalation, have to be considered
for therapeutic intervention. With studies
like the one in this issue of Cell Host &
Microbe, we are just beginning to grasp
the layers of viral regulation of macroau-
tophagy, which can be harnessed for
treatment of viral infections.REFERENCES
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